- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis Severe Crohn disease Complex refractory fistulising Crohn Disease Moderate to severe ulcerative colitis
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Infliximab – July 2025
Infliximab; Powder for I.V. infusion 100 mg; Remsima®
Last updated
9 July 2025